The University of Nebraska Medical Center and Hemispherx Biopharma are partnering to take on pancreatic cancer, one of the most deadly forms of cancer.    In mouse model studies, Hemispherx’s immune-enhancing drug, Ampligen – an immune-enhancer TLR3 agonist – will be administered with a peptide vaccine developed by UNMC.   The study will test the capability of Ampligen to enhance immune responses when combined with a peptide vaccine developed by UNMC for MUC1-positive pancreatic ...